Chiesi Farmaceutici
Chiesi Farmaceutici, a prominent player in the global pharmaceutical industry, is headquartered in Parma, Italy. Founded in 1935, the company has established a strong presence in various operational regions, including Europe, North America, and Asia. Specialising in innovative treatments for respiratory diseases, neonatology, and rare diseases, Chiesi is renowned for its commitment to research and development, which has led to several key milestones in the biopharmaceutical sector. The company’s core products, including advanced inhalation therapies and specialty medicines, are distinguished by their focus on patient-centric solutions. Chiesi Farmaceutici has garnered recognition for its sustainable practices and dedication to improving health outcomes, positioning itself as a leader in the pharmaceutical market. With a rich history and a forward-thinking approach, Chiesi continues to make significant contributions to healthcare worldwide.
DitchCarbon Score
How does Chiesi Farmaceutici's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Chiesi Farmaceutici's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Chiesi Farmaceutici's reported carbon emissions
In 2024, Chiesi Farmaceutici reported total greenhouse gas emissions of approximately 1,022,663,000 kg CO2e. This includes Scope 1 emissions of about 24,653,000 kg CO2e, Scope 2 emissions of approximately 49,600 kg CO2e (market-based) and 12,822,000 kg CO2e (location-based), and significant Scope 3 emissions of around 997,514,000 kg CO2e. For 2023, the company disclosed total emissions of about 980,116,000 kg CO2e globally, with Scope 1 emissions at approximately 29,906,000 kg CO2e, Scope 2 emissions of about 591,000 kg CO2e (market-based) and 12,254,000 kg CO2e (location-based), and Scope 3 emissions reaching around 949,619,000 kg CO2e. Chiesi has set ambitious climate commitments, aiming to achieve a 90% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2019 baseline. Additionally, they plan to reduce Scope 3 emissions from the use of sold products by 90% by 2035. The company is committed to reaching net-zero greenhouse gas emissions across all scopes by 2035, with interim targets approved by the Science Based Targets initiative (SBTi). Chiesi's reduction initiatives include a commitment to cut direct GHG emissions (Scope 1) and indirect emissions from purchased electricity and heat (Scope 2) by at least 50% by 2030 compared to 2019 levels. The company has made progress, reporting a 12% reduction in Scope 1 emissions from 2019 to 2023, primarily due to improvements in their car fleet and stationary emissions. Overall, Chiesi Farmaceutici is actively working towards significant emissions reductions and has established a comprehensive framework to address its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 21,729,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,985,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Chiesi Farmaceutici is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
